Healthcare provider profile · identity verified

Kaberi Chanda, MD

Internal Medicine · TRUMBULL, CT · NPI 1932111481

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	400	110
Amlodipine Besylate	Amlodipine Besylate	324	100
Atorvastatin Calcium	Atorvastatin Calcium	321	101
Rosuvastatin Calcium	Rosuvastatin Calcium	256	76
Pravastatin Sodium	Pravastatin Sodium	165	59
Metformin Hcl	Metformin Hcl	153	49
Lisinopril	Lisinopril	146	49
Sertraline Hcl	Sertraline Hcl	140	37
Omeprazole	Omeprazole	118	39
Escitalopram Oxalate	Escitalopram Oxalate	109	30
Losartan Potassium	Losartan Potassium	100	31
Simvastatin	Simvastatin	88	24
Pantoprazole Sodium	Pantoprazole Sodium	65	19
Hydrochlorothiazide	Hydrochlorothiazide	62	21
Alprazolam	Alprazolam	59	19
Lorazepam	Lorazepam	58	14
Metoprolol Succinate	Metoprolol Succinate	57	19
Albuterol Sulfate Hfa	Albuterol Sulfate	56	27
Zolpidem Tartrate	Zolpidem Tartrate	55	12
Allopurinol	Allopurinol	48	15
Fluticasone Propionate	Fluticasone Propionate	48	19
Gabapentin	Gabapentin	46	14
Jardiance	Empagliflozin	43	suppressed
Ezetimibe	Ezetimibe	41	suppressed
Irbesartan	Irbesartan	40	13
Montelukast Sodium	Montelukast Sodium	40	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	38	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	37	28
Duloxetine Hcl	Duloxetine Hcl	35	suppressed
Eliquis	Apixaban	34	suppressed
Paroxetine Hcl	Paroxetine Hcl	34	11
Alendronate Sodium	Alendronate Sodium	33	12
Citalopram Hbr	Citalopram Hydrobromide	31	suppressed
Januvia	Sitagliptin Phosphate	28	suppressed
Tradjenta	Linagliptin	28	11
Zolpidem Tartrate Er	Zolpidem Tartrate	27	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	26	25
Olmesartan Medoxomil	Olmesartan Medoxomil	26	suppressed
Atenolol	Atenolol	25	suppressed
Carvedilol	Carvedilol	25	suppressed
Furosemide	Furosemide	25	suppressed
Metformin Hcl Er	Metformin Hcl	25	11
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	25	suppressed
Synthroid	Levothyroxine Sodium	25	suppressed
Valsartan	Valsartan	25	12
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	24	suppressed
Cefuroxime	Cefuroxime Axetil	24	24
Esomeprazole Magnesium	Esomeprazole Magnesium	24	suppressed
Meloxicam	Meloxicam	24	suppressed
Mirtazapine	Mirtazapine	24	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	23	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	23	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	23	suppressed
Azithromycin	Azithromycin	22	19
Xarelto	Rivaroxaban	20	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	19	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	19	suppressed
Nebivolol Hcl	Nebivolol Hcl	19	suppressed
Prednisone	Prednisone	19	11
Donepezil Hcl	Donepezil Hcl	17	suppressed
Hydralazine Hcl	Hydralazine Hcl	17	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	17	suppressed
Clonidine Hcl	Clonidine Hcl	16	suppressed
Labetalol Hcl	Labetalol Hcl	16	suppressed
Meclizine Hcl	Meclizine Hcl	15	suppressed
Spironolactone	Spironolactone	15	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	14	11
Celecoxib	Celecoxib	14	suppressed
Tramadol Hcl-Acetaminophen	Tramadol Hcl/Acetaminophen	14	suppressed
Clonazepam	Clonazepam	13	suppressed
Clopidogrel	Clopidogrel Bisulfate	13	suppressed
Famotidine	Famotidine	13	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	13	suppressed
Irbesartan-Hydrochlorothiazide	Irbesartan/Hydrochlorothiazide	13	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	13	suppressed
Valacyclovir	Valacyclovir Hcl	13	suppressed
Benazepril Hcl	Benazepril Hcl	11	suppressed
Cephalexin	Cephalexin	11	suppressed
Clorazepate Dipotassium	Clorazepate Dipotassium	11	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	11	suppressed
Glimepiride	Glimepiride	11	suppressed
Glipizide Er	Glipizide	11	suppressed
Ropinirole Hcl	Ropinirole Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error